The selective estrogen receptor modulators (SERMs), tamoxifen [1] and raloxifene [2], and aromatase inhibitor (AI), exemestane [3], have been shown to reduce breast cancer incidence. The gene discussed is CYP19A1; the disease is breast carcinoma.